Actively Recruiting
A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD
Led by Gan and Lee Pharmaceuticals, USA · Updated on 2024-08-19
60
Participants Needed
1
Research Sites
22 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is conducted in China. The aim of the trial is to compare the efficacy, tolerability, and safety of GZR101 Injection and GZR33-70 Injection in type 2 diabetes inadequately controlled on basal/ premixed insulin once daily at least with or without pre-dinner meal-time insulin.
CONDITIONS
Official Title
A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and able to comply with the study requirements
- Aged 18 to 75 years, male or female
- Negative pregnancy test for women of childbearing potential at screening
- Diagnosed with type 2 diabetes mellitus for 6 months or longer
You will not qualify if you...
- History or presence of cancer before screening
- Known or suspected allergy to study drugs or related products
- Severe hypoglycemia (level 3) within 6 months before screening
- Acute heart failure or hospitalization for coronary heart disease, myocardial infarction, unstable angina, or stroke within 6 months before screening
- Participation in another interventional clinical study within 4 weeks before randomization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Study Site 01
Tianjin, China
Actively Recruiting
Research Team
B
Baozhuo Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here